# Carvone derived cannabidiol enantiomers as novel anticonvulsants

**Authors:** Rochelle M. Hines, April Contreras, Adriana Carrillo, Alexandra Paton, Antonio J. Tenorio, William A. Maio, Dustin J. Hines

PMC · DOI: 10.1038/s41386-025-02220-1 · Neuropsychopharmacology · 2025-09-24

## TL;DR

This study explores new anticonvulsant compounds derived from cannabidiol to treat developmental epilepsy with fewer side effects.

## Contribution

The study introduces carvone-derived CBD enantiomers as novel anticonvulsants with improved efficacy and safety.

## Key findings

- Elongated alkyl chains in CBD congeners increase potency, particularly in δ and θ frequency bands.
- Pre-treatment with (+)-CBD-oct reduces seizures and mortality in epilepsy models.
- CBD-oct normalizes dendritic spine abnormalities in developing mice.

## Abstract

Developmental epilepsy syndromes are characterized by recurrent seizures and developmental delays. Current anticonvulsants target γ-aminobutyric acid type A receptor signaling to decrease neuronal excitability, however, there are adverse effects for the developing brain, and many patients are refractory. The major non-psychotropic phytocannabinoid cannabidiol (CBD) has emerged as an anti-seizure medication effective in select developmental epilepsy syndromes, but its overall applicability in treating seizure disorders is limited. In the present study, we characterize a small library of non-Cannabis carvone derived CBD (+) enantiomers, with the larger goal of identifying novel therapeutics for developmental epilepsy syndromes. EEG based structure activity relationship assessment supports that elongated alkyl chains increase the potency of the congeners, with (+)-CBD-oct displaying effects on both δ and θ frequency bands. Pre-treatment with (+)-CBD-oct promotes seizure resilience in both wildtype mice and the Gabra2-1 model of developmental epilepsy by influencing seizure characteristics, and reduces mortality. 5 days of (+)-CBD-oct oral gavage in wildtype and Gabra2-1 mice during postnatal development normalizes the aberrant dendritic spine phenotype of Gabra2-1 mice. These findings advance the development of novel anticonvulsants by validating an influence of alkyl chain length of synthetic CBD congeners.

## Linked entities

- **Genes:** GABRA2 (gamma-aminobutyric acid type A receptor subunit alpha2) [NCBI Gene 2555]
- **Chemicals:** cannabidiol (PubChem CID 644019), carvone (PubChem CID 7439)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** Developmental epilepsy syndromes (MESH:D000073376), seizure (MESH:D012640), developmental delays (MESH:D002658), developmental epilepsy (MESH:D004827)
- **Chemicals:** Carvone (MESH:C006923), (+)-CBD-oct (-), CBD (MESH:D002185)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12603161/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12603161/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12603161/full.md

---
Source: https://tomesphere.com/paper/PMC12603161